The Belgium-based company, founded as a spin-off of the Catholic University of Leuven and the University of Ghent, is developing a portfolio of products that addresses specific musculoskeletal problems, with a lead indication being cartilage damage. TiGenix exploits the anti-inflammatory properties of stem cells to develop therapies for serious medical conditions in the areas of high unmet medical need, with product candidates including Cx601, Cx611, and AlloCSC-01 targeting autoimmune, inflammatory, and heart diseases.